Cipla North America Partners with American Lung Association for 2025 LUNG FORCE Walk to Champion Respiratory Health

NEW YORK, May 27, 2025 /PRNewswire/ -- Cipla USA Inc. (Cipla USA) announced its continued collaboration with the American Lung Association for the 11^th annual LUNG FORCE Walk, reaffirming its commitment to advancing respiratory health and supporting those affected by lung disease. For the 3^rd consecutive time, Cipla North America employees joined hundreds of participants at the iconic South Street Seaport, Pier 16 in New York City, walking in solidarity to raise awareness and funds for lung health initiatives.

As a Lead Sponsor of this year's walk, Cipla USA continues to build on its legacy of over 10 years in the US generics pharmaceutical landscape, with a strong focus on respiratory care. With more than 34 million Americans¹ living with chronic lung diseases, the company's purpose of 'Caring for Life' remains more relevant than ever. This year, Cipla proudly recorded its highest-ever participation in the walk, with nearly 100 employees, along with their families and friends, joining the event. This notable turnout also made Cipla the largest participating group on the day, marking a significant milestone in the ongoing commitment to community engagement.

Marc Falkin, CEO, Cipla North America, said, "Our collaboration with the American Lung Association underscores our steadfast commitment to expanding access to high-quality, innovative treatments and raising awareness about respiratory diseases. Events like the LUNG FORCE Walk unite communities and inspire action toward a healthier future. With a legacy rooted in respiratory innovation, Cipla remains dedicated to helping people breathe freely and live better."

"We're incredibly grateful for Cipla USA's continued leadership and commitment to lung health," said Emily Amitin, Development Director of the American Lung Association in Metro New York. "Their support helps fuel lifesaving research, expand access to care, and amplify awareness around the most pressing respiratory issues facing our communities. Together, we're not just walking - we're driving progress for every person who breathes."

The LUNG FORCE Walk supports the American Lung Association's efforts to defeat lung cancer, improve air quality, reduce the burden of lung disease, and eliminate tobacco use. According to the ALA, asthma affects approximately 27.8 million Americans, and chronic obstructive pulmonary disease (COPD) impacts 11.1 million adults. Lung cancer remains the leading cause of cancer-related deaths in the U.S.

Cipla USA is committed to supporting initiatives that align with its vision of enabling people to live healthier lives. The company looks forward to continuing its partnership with the American Lung Association and contributing to impactful change in respiratory care.

About Cipla:

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets. A responsible corporate citizen, Cipla's humanitarian approach to healthcare in pursuit of its purpose of 'Caring for Life' and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers, and all stakeholders. Cipla USA is a respiratory leader, ranking #2 in inhaler sales globally and in the top 3 for US generic respiratory sales (IQVIA TRx data as of February 2025). For more information about Cipla and its commitment to respiratory health, please visit Cipla's USA website at www.ciplausa.com.

¹ https://www.lung.org/research/trends-in-lung-disease/prevalence-incidence-lung-disease 

Logo: https://mma.prnewswire.com/media/947146/1865863/Cipla_Logo.jpg

SOURCE Cipla